NMRA · Neumora Therapeutics, Inc. · Webcasts, Transcripts & Audio
$0.33
-0.01 (-3.78%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Nov 16, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Nov 16, 2026
Market Cap
$63.01M
Shares
188.69M
Volume · Nov 20
1.06M
Avg daily vol (3M)
1.67M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Neumora Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Neumora Therapeutics, Inc. (NMRA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Annual General Meeting
Investor event
2026-05-27
Neumora Therapeutics, Inc. (NMRA) May 27, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Neumora Therapeutics, Inc. (NMRA) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-04-13
Neumora Therapeutics, Inc. (NMRA) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-30
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Confident tone
NMRA-215 obesity program and rat tox findings
M4 PAM franchise / NMRA-898 in schizophrenia
NMRA-511 in Alzheimer's disease agitation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-05
Neumora Therapeutics, Inc. (NMRA) January 5, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q2
2025-08-06
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Confident tone
Obesity / NMRA-215 NLRP3 inhibitor lead indication
M4 PAM franchise (NMRA-861, NMRA-898)
Navacaprant KOASTAL Phase III in MDD
Diluted EPS
$-0.33
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Positive tone
KOASTAL Phase 3 program (navacaprant in MDD)
KOASTAL-1 failure and study modifications
NMRA-511 in Alzheimer's disease agitation
Diluted EPS
$-0.42
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Positive tone
Navacaprant (KOASTAL Phase 3 program in MDD)
Regulatory engagement and trial design
Leadership transitions
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Confident tone
Navacaprant / KOASTAL Phase 3 program in MDD
Pipeline breadth and additional programs
Clinical validation and safety profile
Diluted EPS
$-0.45
Audio
Transcript
Slides
8-K10-Q
Showing 1–9 of 9 webcasts
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
143 filings
117 filers
Visit website
Investor relations